The pain from a migraine can be painful, but it can also be life-changing, so a new product could offer relief.
Researchers in France and Italy have developed a pill that has been shown to reduce pain and inflammation in the brain.
The pill is the first to be tested in humans, the researchers said.
“The main objective is to improve pain perception,” said Dr. Guillaume R. Deschamps, an assistant professor of psychiatry at the University of Nice, who was not involved in the study.
“It may be that this pill can be used in conjunction with other medications for pain relief.”
The researchers say the pill, called TNF-1, is a “cure” for migraines, a condition in which the body produces too much of a pain hormone called torsade de pointes, or DPD.
The pain caused by a migraine lasts for as long as four hours.
It’s possible the pill could also have some potential to treat other types of pain, including muscle pain.
In addition to relieving pain, the pill has been tested on people who suffer from Crohn’s disease, a chronic inflammatory condition that causes inflammation in certain parts of the body.
“This pill has a potential to be useful for people with pain that is aggravated by inflammatory disorders,” Deschamp said.TNF-4 is a molecule in blood that also inhibits the production of inflammatory molecules.
“It is a very important molecule for inflammation,” said Jean-Pierre Chabrol, an associate professor of neurology at the Paris Polytechnic Institute.
“We are interested in finding out how to reduce inflammation.”
The French and Italian researchers also believe their pill could be helpful for people who have other health problems, such as chronic heart disease.
The study was published Monday in the journal Neurology.
The researchers tested the pill in mice for an initial period of about eight weeks.
The results were promising.
The mice, which were injected with the pills daily for eight weeks, had significantly less inflammation than mice who were not injected with TNF4.
The mice also had significantly fewer symptoms of migrainias, including more frequent headache attacks.
“We have to look at other aspects of the treatment, such the dosage,” Deshamps said.
“Our aim is to make this pill more safe and more effective.”
If the pill is taken daily, Deshamp said the researchers expect to see improvement in about a third of the mice.
The French researchers are now testing whether the pill can work in humans.
“I hope it will be tested and approved by the FDA in the near future,” Deshpbs said.
The TNF1 is currently a Phase 3 trial, which means the researchers are working on the next stage.